Mar 3 2010
CaridianBCT, a leading global provider of technology, products and
services in automated blood collections, therapeutic apheresis and cell
therapy systems, whole blood processes and pathogen reduction
technologies announced it has received 510(k) clearance for the Trima
Accel® Automated Blood Collection System Version 6.0—providing increased
efficiencies and streamlined operations to blood centers.
“This is a major product enhancement for our flagship automated blood
collection system”
“This is a major product enhancement for our flagship automated blood
collection system,” said David Perez, president and chief executive
officer of CaridianBCT. “The Trima Accel Version 6.0 demonstrates our
ongoing commitment to provide customers with a flexible platform,
providing the most blood component collection options to maximize a
blood center’s operations and realize greater productivity—whether in
fixed or mobile sites.”
The latest version of the Trima Accel system includes the Auto Red Blood
Cell (RBC) procedure, allowing for the collection of a
ready-to-transfuse leukoreduced red blood cell product from donors and
eliminating the requirement for post-procedure leukoreduction and
addition of storage solution.
“The Trima Accel V6.0 Auto RBC procedure brings a host of improvements
and additional ease-of-use to blood centers and helps them meet the
changing blood supply needs of hospitals,” said Bob Cole, senior vice
president of CaridianBCT’s Automated Collections business area. “By
increasing efficiencies through streamlining operations and reducing the
opportunities for error, the Auto RBC procedure will benefit blood
centers.”
After receiving 510(k) clearance on February 16, 2010, CaridianBCT plans
to launch Trima Accel system V6.0 in multiple markets around the world
over the next several months.